Matthew Mei

Has grant

Associate Professor

City of Hope

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Matthew Mei is an Associate Professor at City of Hope in the United States. His research areas primarily focus on innovative therapies for hematologic malignancies, including CAR-T therapy, high-dose chemotherapy regimens for germ cell tumors, and novel treatment combinations for Hodgkin lymphoma. He has contributed significantly to understanding the long-term outcomes of autologous stem cell transplantation and the implications of clonal hematopoiesis in heart failure post-transplant.

Recent Grants

Grant: Close

The Impact of Somatic Mutations on Allogeneic Transplantation Outcomes in Chronic Myelomonocytic Leukemia

Open Date:

Close Date:

Articles (20)

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

UNITED STATES

View details

Swaminathan P. Iyer

Professor of Medicine

The University of Texas MD Anderson Cancer Center

UNITED STATES

View details

Jose Tinajero

City of Hope

UNITED STATES

View details

George Georges

Professor

Feinberg School of Medicine

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Matthew Mei

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (20)

Autologous Nonmyeloablative Hematopoietic Stem Cell Transplantation for Diffuse Cutaneous Systemic Sclerosis: Identifying Disease Risk Factors for Toxicity and Long‐Term Outcomes in a Prospective, Single‐Arm Trial

Real‐world experience with CAR‐T therapy in relapsed and refractory follicular lymphoma

Multicenter analysis of high-dose chemotherapy regimens for the treatment of patients with refractory or recurrent germ cell tumors.

Nivolumab plus ifosfamide, carboplatin, and etoposide are a highly effective first salvage regimen in high‐risk relapsed/refractory Hodgkin lymphoma

Tyrosine kinase inhibitor maintenance following chimeric antigen receptor T‐cell therapy in Philadelphia chromosome‐positive acute lymphoblastic leukaemia

Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study.

Glofitamab in patients with HIV-associated B-cell lymphoma.

Clonal Hematopoiesis and Risk of Heart Failure After Autologous Hematopoietic Cell Transplantation for Lymphoma.

Nivolumab+AVD in Advanced-Stage Classic Hodgkin's Lymphoma.

Prognostic significance of fludeoxyglucose positron emission tomography delta radiomics following bridging therapy in patients with large B-cell lymphoma undergoing CAR T-cell therapy.

ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma

Bendamustine lymphodepletion is a well‐tolerated alternative to fludarabine and cyclophosphamide lymphodepletion for axicabtagene ciloleucel therapy for aggressive B‐cell lymphoma

Pembrolizumab plus vorinostat is highly active in Hodgkin lymphoma, including patients refractory to prior PD-1 blockade

Results of a Phase II Trial of Allogeneic Hematopoietic Stem Cell Transplantation Using 90Y-Ibritumomab Tiuxetan (Zevalin) in Combination With Fludarabine and Melphalan in Patients With High-Risk B-Cell Non-Hodgkin's Lymphoma

Results from a phase I trial of pembrolizumab plus vorinostat in relapsed/refractory B-cell non-Hodgkin lymphoma.

Thrombopoietin Receptor Agonists for Thrombocytopenia Secondary to HER2-Targeted Antibody Drug Conjugates.

The next frontier: enter PD-1 and exit PET scans?

Can we cure relapsed/refractory Hodgkin lymphoma without a stem cell transplant?

Association Between Pretreatment Skeletal Muscle and Outcomes After CAR T-Cell Therapy.

Autologous Stem Cell Transplantation with Intensity Modulated Total Body Irradiation Conditioning for Systemic Sclerosis.

Collaborators (11)

Catherine Lee

Lihua Budde

Geoffrey Shouse

Jennifer Holter Chakrabarty

James Godfrey

Maureen Mayes

Yuan Yuan

Jennifer R. Simpson

Swaminathan P. Iyer

Jose Tinajero

George Georges

Make your next move.